Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis

Jinping Sun, Zheng Ren, Xinfang Sun, Hongtao Hou, Ke Li and Quanxing Ge _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:39673-39682. https://doi.org/10.18632/oncotarget.17784

Metrics: PDF 1734 views  |   HTML 2172 views  |   ?  


Jinping Sun1,*, Zheng Ren1,*, Xinfang Sun1, Hongtao Hou1, Ke Li1, Quanxing Ge1

1Department of Digestive Internal Medicine, Huaihe Hospital of Henan University, Kaifeng, 475000, Henan, China

*These authors contributed equally to this work

Correspondence to:

Quanxing Ge, email: [email protected]

Keywords: advanced gastric cancer, chemotherapies, network meta-analysis, efficacy, safety

Received: February 07, 2017     Accepted: April 03, 2017     Published: May 11, 2017


Objective: Chemotherapy is one of the commonly used therapies for advanced gastric cancer. In this study, we performed a network meta-analysis on the efficacy and safety of common treatments to give evidences of their relative benefits.

Results: 32 trials with 8550 patients and 20 regimens were included in this study. According to the results of primary outcomes, 5-FU plus OXA, 5-FU plus DOC, CAP plus CIS, CAP plus OXA, S-1 plus OXA and S-1 plus PAC performed well in improving OS and ORR. As for the adverse events, S-1 had a safer effect than other treatments, conversely, 5-FU plus CIS ranked the last. However, there was no regimen with outstanding performances in both efficacy and safety.

Materials and Methods: Studies were searched from database and screened with criteria. The Bayesian framework based network meta-analysis was performed with software R and STATA. Overall survival (OS) and overall response rate (ORR) were considered as primary outcomes while adverse events as secondary outcomes. The outcomes were represented by hazard ratios or odd ratios with 95% corresponding credible intervals, respectively.

Conclusions: The network meta-analysis suggested that 5-FU plus OXA and 5-FU plus DOC were recommended when efficacy was stressed. S-1 was safest but poorly effective. A regimen, as an excellent combination of efficacy and safety, is still waiting to be discovered.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17784